Bibliographic Details
| Title: |
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. |
| Authors: |
Awada G; Departments of Medical Oncology., Schwarze JK; Departments of Medical Oncology., Tijtgat J; Departments of Medical Oncology., Fasolino G; Ophthalmology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels., Kruse V; Department of Medical Oncology, Universitair Ziekenhuis Gent, Ghent.; Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas (current affiliation).; Ghent University, Ghent (current affiliation).; University of Antwerp, Antwerp, Belgium (current affiliation)., Neyns B; Departments of Medical Oncology. |
| Source: |
Melanoma research [Melanoma Res] 2022 Jun 01; Vol. 32 (3), pp. 183-191. Date of Electronic Publication: 2022 Mar 29. |
| Publication Type: |
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: |
Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5636 (Electronic) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
